X Bioscience Public Company Limited

As of June 30, 2026, X Bioscience Public Company Limited NVDR carries a market capitalization of 851.46M, placing it among publicly traded companies globally. Its enterprise value stands at 1.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, X Bioscience Public Company Limited NVDR has 12.16B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.52, and the price-to-book ratio stands at 2.89.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.04B versus a market cap of 851.46M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, X Bioscience Public Company Limited NVDR maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.12, indicating elevated leverage, while an interest coverage ratio of -32.94 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, X Bioscience Public Company Limited NVDR posted a negative return on equity (ROE) of -184.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -83.96, reflecting losses generated across the asset base. Inventory turnover of 23.78 indicates how many times X Bioscience Public Company Limited NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, X Bioscience Public Company Limited NVDR recorded an income tax benefit of -13.86M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -705.10M and -654.66M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, X Bioscience Public Company Limited NVDR's stock has declined approximately 72.37% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, X Bioscience Public Company Limited NVDR generated 209.49M in revenue and converted that into -654.66M in net income, yielding earnings per share of -0.09. EBITDA reached -663.69M, while operating income came in at -549.07M.

As of June 30, 2026, X Bioscience Public Company Limited NVDR holds 5.30M in cash and equivalents against 129.26M in total debt, resulting in a net debt position of 114.13M. Total book value stands at 294.99M, with working capital of 82.16M providing operational flexibility.

X Bioscience Public Company Limited NVDR produced -179.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -172.82M in capital expenditures, free cash flow totaled -352.01M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, X Bioscience Public Company Limited NVDR posted a gross margin of 39.96, reflecting its pricing power and cost economics. The operating margin of -262.10 and net profit margin of -312.51 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, X Bioscience Public Company Limited NVDR paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -66.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -48.39, meaning X Bioscience Public Company Limited NVDR raised more capital through share issuance and new debt than it returned via dividends and buybacks.

X Bioscience Public Company Limited NVDR's most recent stock split took place on January 9, 2026 with a 33:62 split ratio.

As of June 30, 2026, X Bioscience Public Company Limited NVDR has an Altman Z-Score of -6.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.